Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIBRONEER™-ON: Open-label Extension Trial of Nerandomilast in IPF and PPF
NCT06238622Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 44
01
Overview
Phase 3, open-label, single-arm trial of nerandomilast in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of any adverse event at 99 weeks. Started Sep 2024; status: active, not recruiting.
02
Drugs
nerandomilast
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT06238622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238622.